by Alex Acevedo | Feb 3, 2026 | Lupus Foundation of America, News & Events, Research News
This afternoon, Congress took the final steps in the FY 2026 budget process, passing legislation that increases funding for lupus programs, including $27 million – the most in history – for lupus programs at the Centers for Disease Control and Prevention (CDC),...
by Lupus Foundation, Ohio | Feb 3, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC), self-administration of Saphnelo (anifrolumab). AstraZeneca has...
by Lupus Foundation, Ohio | Feb 3, 2026 | Lupus Foundation of America, News & Events
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in people with progressive and treatment-resistant systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM) and systemic lupus erythematosus...
by Lupus Foundation, Ohio | Jan 30, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug, litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE, a chronic autoimmune skin disease). This designation is given only to...
by Lupus Foundation, Ohio | Jan 15, 2026 | Lupus Foundation of America, News & Events
In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen autoimmune skin conditions, such as in people with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE). They identified 227...
by Lupus Foundation, Ohio | Jan 11, 2026 | Lupus Foundation of America, News & Events
AstraZeneca reported positive results from a Phase III TULIP-SC clinical trial, showing a statistically significant and clinically meaningful reduction in disease activity with the subcutaneous (SC), self-administration of Saphnelo (anifrolumab) in adults with...
